The UK stock market's FTSE 100 is up firmly in positive territory Friday morning, led by gains in the mining sector. Investors are also reacting to a slew of earnings news and other corporate announcements. Data showing an unexpected drop in consumer confidence is limiting market's upside.The benchmark FTSE 100, which advanced to 10,914.18, a new record high, was up 43.34 points or 0.4% at 10,890.04 a few minutes ago.RightMove, up 4.2%, tops the list of gainers in the FTSE 100 index. The stock is up after ...

Summary of Compugen's Conference Call Company Overview - **Company**: Compugen (Ticker: CGEN) - **Industry**: Biotechnology, specifically focused on oncology and immunotherapy Key Points Discussed Pipeline and Development Focus - Compugen is focusing on its pipeline assets, particularly **COM701**, which targets the **PVRIG** pathway, a novel checkpoint with distinct biology compared to PD-1 and TIGIT [4][5] - The rationale for targeting PVRIG is its dominance in ovarian cancer, which is a less inflamed tumor type, making it a challenging indication [4] - Clinical studies have shown that **COM701** can elicit responses in patients with platinum-resistant ovarian cancer, particularly those who are PD-1 negative [5][6] Clinical Trial Insights - The company is conducting a randomized study (MAIA) with **60 patients** who are platinum-sensitive, comparing **COM701** monotherapy to placebo [10] - Historical control data suggests a progression-free survival (PFS) of **5.5 months**, with Compugen aiming to extend this by **3 months** with COM701 [11] - In the last line of treatment, **40%** of patients showed clinical benefit with a durable PFS of **10.5 months** [10] Market Opportunity and Unmet Need - There is a significant unmet need in earlier lines of treatment for platinum-sensitive ovarian cancer patients, which COM701 aims to address [7] - The potential market opportunity for COM701 is substantial, given the lack of standard care in this patient population [7] Competitive Landscape - Compugen is the first to move PVRIG into clinical trials, with some early programs from other companies also exploring this target [21] - The discussion highlighted the differentiation of Compugen's approach from other candidates in the TIGIT space, particularly focusing on the safety profile of their Fc-reduced format compared to Fc-active formats that have faced challenges [23][24] Financial Aspects - Compugen has a partnership with **AstraZeneca** for **rilvegostomig**, with potential milestones totaling **$195 million** and mid-single-digit tiered royalties [36][38] - The company has also monetized a portion of future royalties, receiving **$65 million** upfront, which supports ongoing development [38] Other Assets and Collaborations - Compugen is also developing **GS-0321**, an antibody against the IL-18 binding protein in collaboration with **Gilead**, which is currently in phase one trials [39][40] - The structure of the deal with Gilead includes **$60 million** upfront and potential milestones of **$758 million** along with low double-digit royalties [48] Future Outlook - Compugen is exploring new biological targets and plans to continue leveraging its AI-based computational engine for future developments [49][50] - The company is cautious about providing timelines for new announcements, emphasizing the need for validation before committing to guidelines [50] Industry Context - The call addressed the recent disappointments in the TIGIT space, particularly referencing **Arcus** and their failed trials, while highlighting how Compugen's strategies differ [52][53] - AstraZeneca's ongoing studies and their approach to combining rilvegostomig with other therapies were discussed as a promising avenue for success [30][31] Conclusion - Compugen is positioned to address significant unmet needs in oncology, particularly in ovarian cancer, with a strong pipeline and strategic partnerships that could lead to substantial market opportunities in the future.

Aprea Therapeutics (NasdaqCM:APRE) FY Conference February 26, 2026 08:40 AM ET Company ParticipantsOren Gilad - President and CEONone - AssociateNoneMorning, everyone, thanks for joining us. My name is Anthony, and I'm an associate here at Oppenheimer. It's my pleasure to introduce Aprea Therapeutics, a precision oncology company focused on targeting the DNA damage response pathway. Their lead program is APRN-1051, a next-gen WEE1 inhibitor. The company is also advancing ATRN-119, a macrocyclic ATR inhibito ...

GoodRx (NasdaqGS:GDRX) Q4 2025 Earnings call February 26, 2026 08:00 AM ET Company ParticipantsAubrey Reynolds - Director of Investor RelationsCameron Harbilas - Equity Research AssociateChris McGinnis - CFOJohn Ransom - Managing DirectorLaura Jensen - Chief Commercial Officer and President of Pharma DirectLisa Gill - Managing DirectorSteven Valiquette - Managing DirectorWendy Barnes - CEOConference Call ParticipantsAllen Lutz - Senior Equity Research AnalystDaniel Grosslight - Senior Research AnalystGeorge ...

Transitioned from a vertically integrated COVID-19 vaccine manufacturer to a lean, R&D-focused licensing organization centered on the Matrix-M adjuvant technology. Secured over $800 million in non-dilutive capital over 18 months through strategic milestones and upfront payments from Sanofi and Pfizer. Leveraged the Pfizer agreement to validate Matrix-M's utility across diverse disease areas, with potential for billions in long-term revenue through milestones and royalties. Optimized the operational ...

Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 20-F (Mark One) OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 19 ...

Group 1 - Medtronic's MiniMed Group is targeting to raise up to $784 million in its initial public offering (IPO) in the United States [1] - The IPO is part of Medtronic's strategy to enhance its diabetes business and expand its market presence [1]

Core Viewpoint - AstraZeneca CEO Pascal Soriot's pay for 2025 has increased by 6.4% to approximately $24 million, primarily due to higher annual bonuses, maintaining his position among the highest-paid executives in the FTSE 100 [1]. Group 1: CEO Compensation - Pascal Soriot's total pay for 2025 is reported at 17.7 million pounds ($23.87 million) [1]. - The annual bonus for Soriot reached 4.3 million pounds, reflecting a 22% increase from the previous year [1]. Group 2: Company Performance - AstraZeneca is noted as London's most valuable company, with a significant increase in earnings reported for 2025 [1].

Core Viewpoint - Avacta Therapeutics has demonstrated that its proprietary pre|CISION platform offers significant advantages over the marketed antibody drug conjugate (ADC) Enhertu, with plans to initiate a clinical trial for FAP-Exd (AVA6103) in Q1 2026 [1][3]. Group 1: Clinical Data and Comparisons - The analysis compares the delivery profile of pre|CISION FAP-cleavable payload with Enhertu, which is approved for breast and gastric cancer [3]. - The pre|CISION platform shows three key advantages: faster drug penetration into tumors, a higher maximum drug concentration in tumors, and a nearly three-fold higher Tumor Selectivity Index compared to Enhertu [4][9]. - The maximum concentration (Cmax) of FAP-Exd in tumor tissue occurs within minutes, while T-Dxd reaches its maximum concentration at 24 hours [9]. Group 2: Mechanism and Efficacy - The pre|CISION delivery mechanism is designed to selectively deliver potent payloads to tumors while minimizing exposure to normal tissues, enhancing safety and effectiveness [11][13]. - The analysis indicates that FAP-Exd shows higher activity in tumor models with low FAP expression compared to T-Dxd's variable activity at low HER2 expression levels [7]. - Deep and durable responses were observed with FAP-Exd, persisting for weeks after a three-dose regimen [7]. Group 3: Future Plans and Innovations - Avacta plans to present these findings at an upcoming scientific congress and submit them to a peer-reviewed journal [8]. - The use of AI to create a synthetic comparator arm for data analysis highlights the innovative approach of the company's research team [5][6].

Core Viewpoint - AIM ImmunoTech Inc. is advancing its Phase 2 clinical study of Ampligen in combination with AstraZeneca's Imfinzi for treating metastatic pancreatic cancer, with promising early results and a commitment to ongoing updates [1][2][4]. Group 1: Clinical Study Details - The DURIPANC study is an exploratory, open-label trial with 18 subjects enrolled, focusing on patients with stable disease post-FOLFIRINOX [2]. - The study is a collaboration between AIM, AstraZeneca, and Erasmus Medical Center, with interim progress reports planned for mid-year and year-end [2]. - The lead investigator reported continued promising results in Progression-Free Survival and Overall Survival from Phase 1, supporting the ongoing Phase 2 study [2]. Group 2: Safety and Quality of Life - There has been no significant toxicity reported, indicating a favorable safety profile for Ampligen in a post-chemotherapy setting [3]. - Subjects receiving Ampligen have consistently reported a "high quality of life" during treatment [3]. Group 3: Future Milestones - Key milestones include completing subject enrollment by July 2026, full dosing by August 2026, and evaluating primary and secondary endpoints by December 2026 and June 2027, respectively [5]. - The primary endpoint is the Clinical Benefit Rate at 6 months, while secondary endpoints include Progression-Free Survival, Overall Survival, and immunogenic efficacy [5]. Group 4: Corporate Strategy - AIM emphasizes the potential for Ampligen's approval in pancreatic cancer, viewing this research as a significant opportunity for stockholders [4]. - The company aims to advance Ampligen towards Phase 3 clinical trials, which are often associated with substantial financial opportunities in the biotech sector [4].